Fernando Girón-Luque

Fernando Girón-Luque

Auto-generated profile, based on publicly available information

Fernando Girón-Luque

Colombiana de trasplantes

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2005 in Transplantation Proceedings
Verified
Journal Article
Closed access
PMP. Massari
P. Massari
VDV. Duro-Garcia
V. Duro-Garcia
FGF. Girón
F. Girón
EHE. Hernández
E. Hernández
FJF. Juárez
F. Juárez
MTM. Toledo
M. Toledo

1 April 2008 in Transplantation Proceedings
Verified
Journal Article
Closed access
YBY. Baez
Y. Baez
FGF. Giron
F. Giron
ANA. Niño-Murcia
A. Niño-Murcia
JRJ. Rodríguez
J. Rodríguez
SSS. Salcedo
S. Salcedo

28 August 2023 in Universitas Médica
Verified
Journal Article
Open access
PDF file
AGAndrea Garcia-Lopez
Andrea Garcia-Lopez
FGFernando Girón-Luque
Fernando Girón-Luque
DRDiego Rosselli
Diego Rosselli
El desarrollo de la inteligencia artificial (IA), así como la mejora evidente que han tenido las tecnologías digitales en el campo de la salud, obliga a plantearnos dos preguntas importantes que surgen al incorporar la IA como instrumento para una mejora en la calidad de atención. 1) ¿Podrá la IA reemplazar a los médicos? y 2) ¿Cuáles son las consideraciones éticas de la implementación de la IA en el campo de la salud? Concluimos que, con algunas pocas excepciones, por ahora la IA no parece que pueda sustituir al ser humano, pero sí lo puede complementar y extender su labor. Existen tres consideraciones éticas en el uso de la IA: el paciente debe estar informado del uso de estos sistemas; los profesionales de la salud deben conocer y aprender sobre la tecnología que se va a implementar, además asegurarse de que traerá un beneficio para el paciente, y, por último, se vuelve fundamental aplicar los principios básicos de la ética médica.

29 April 2008 in Transplantation Proceedings
Verified
Journal Article
Closed access
FGF. Giron
F. Giron
YBY. Baez
Y. Baez
ANA. Niño-Murcia
A. Niño-Murcia
JRJ. Rodríguez
J. Rodríguez
SSS. Salcedo
S. Salcedo

28 September 2022 in Research and Reports in Urology
Verified
Journal Article
Open access
PDF file
LNLaura Nino-Torres
Laura Nino-Torres
AGAndrea Garcia-Lopez
Andrea Garcia-Lopez
NPNasly Patino-Jaramillo
Nasly Patino-Jaramillo
FGFernando Giron-Luque
Fernando Giron-Luque
ANAlejandro Nino-Murcia
Alejandro Nino-Murcia
Background and Purpose: Kidney transplantation (KT) is the best therapy for chronic kidney disease (CKD). Major urologic complications (MUCs) are the second etiology associated to morbidity and graft loss following KT, after rejection episodes. The objective of this study was to estimate the incidence, risk factors and impact on graft survival associated to urological complications in KT patients. Patients and Methods: A retrospective cohort based on electronic patient files of kidney transplant recipients from Colombiana de Trasplantes was created for the period August 2008 to September 2019. Initiation of follow-up was defined as the date of transplantation up to 3 years post-transplantation. Incidence of ureteral stenosis, ureteral obstruction, and ureteral leak was measured. A logistic regression multivariate model was adjusted to determine the associated factors to MUCs (yes/no). Patient and graft survival time were analyzed using a Kaplan-Meier method. Results: A total of 1584 KT patients were included in the cohort. MUCs were present in 195 (12.6%) KT patients. We found that dialysis duration (OR: 1.004; p = 0.02) remained significant for the incidence of MUCs in KT patients of deceased donors. Probability of graft and patient survival at 3 years of follow-up was 90.5% and 85.5%, respectively. No significant difference was found on graft and patient survival in KT patients with or without MUCs. Conclusion: MUCs are frequent complications for KT. We did not observe significant differences in graft or patient survival according to the presence of MUCs. The identification of MUCs and risk factors may guide transplant teams for future surgical and clinical decisions.

26 February 2024 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
LNLaura Nino-Torres
Laura Nino-Torres
JPJessica Pinto-Ramirez
Jessica Pinto-Ramirez
FGFernando Giron-Luque
Fernando Giron-Luque
ANAlejandro Nino-Murcia
Alejandro Nino-Murcia
Background: In chronic kidney disease (CKD), there are historical inequities in multiple stages of the pathway for organ transplantation. Women have been recognized as disadvantaged within this process even after several efforts. Therefore, we aimed to analyze the prevalence and incidence of CKD by gender and their access to Kidney replacement therapy (KRT) in Colombia. Methods: A cross-sectional study based on secondary analysis of national information on CKD, hypertension, diabetes, waiting list, deceased, and living donor transplantation between 2015 and 2020. Results: In Colombia, 4.934.914 patients were diagnosed with hypertension, diabetes, or CKD. 60,64% were female, with a mean age of 63.84 years (SD 14,36). Crude incidence for hypertension (10.85 vs. 7.21 /1000 inhabitants), diabetes mellitus (3.77 vs. 2.98 /1000 inhabitants), and CKD (4 vs. 2 /1000 inhabitants) was higher for females. Crude incidence for KRT was 86.45 cases /100.0000 inhabitants. In 2020, 2978 patients were on the waiting list, 44% female. There were 251 deaths on the waiting list, 38% female. This year, 517 kidney transplants were performed, and only 40% were female. Conclusion: In Colombia, there are proportionally more females with CKD and precursor comorbidities. Nevertheless, there are fewer females on the waiting list and transplanted annually.